Moderna is evaluating a bivalent anti-Covid booster vaccine (mRna-1273.214) that combines the currently licensed vaccine also as a booster with a booster candidate specific for Omicron variants. Initial results of the study, clinical phase 2-3, are expected in the second quarter of the year and this bivalent product “remains our main candidate for a booster dose” to be administered “in the Northern Hemisphere in the fall of 2022”, explains the CEO of the American company, Stéphane Bancel. “We look forward to sharing initial data on mRna-1273.214 in the second quarter – adds the CEO – We believe that a bivalent booster vaccine, if authorized, would represent a new tool” to protect against Covid-19, “while we continue to respond to emerging variants “of the SARS-CoV-2 coronavirus.